



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

July 15, 2020

The Manager - CRD
M/s. BSE Limited
Dalal Street, Fort
Mumbai 400 001
Scrip Code: 524816

The Manager - Listing
M/s. National Stock Exchange of India Ltd
Exchange Plaza, Bandra Kurla Complex,
Bandra (E) **Mumbai 400 051**
Scrip Code: NATCOPHARM

Dear Sir,

Sub: Regulation 23(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Pursuant to Regulation 23(9) of the SEBI (LODR) Regulations, 2015, we are enclosing herewith a disclosure of Related Party Transactions for the year ended March 31, 2020.

Kindly take the above on your records

Thanking you,

Yours faithfully,
For NATCO Pharma Limited

A handwritten signature in black ink, appearing to read "M Adinarayana".

M Adinarayana
Company Secretary &
Vice President (Legal & Corp. Affairs)

(a) Names of the related parties and nature of relationship (to the extent transactions have taken place during the year)

Nature of relationship	Names of the related parties
1. Subsidiary company	NATCO Pharma Inc., United States of America Time Cap Overseas Limited, Mauritius NATCO Pharma (Canada) Inc., Canada NATCO Pharma Asia Pte. Ltd., Singapore NATCO Pharma Australia PTY Ltd., Australia NATCO Lifesciences Philippines Inc., Philippines
2. Step-down subsidiary company	Natcofarma Do Brasil Ltda., Brazil
3. Entities in which Directors have control or have significant influence	Time Cap Pharma Labs Limited NATCO Trust
4. Key management personnel ("KMP")	
Chairman and Mangaing Director	Mr. V C Nannapaneni
Vice Chairman and Chief Executive Officer ("CEO")	Mr. Rajeev Nannapaneni
Wholtime Director	Mr. Potluri Prasad Sivaramakrishna
Wholtime Director	Mr. Lingarao Donthineni
Chief Financial Officer	Mr. S.V.V.N. Appa Rao
Company Secretary	Mr. Adinarayana M
5. Non-Executive Directors and Independent Directors	
Independent Director	Mr. Sreerama Murthy Gubbala
Independent Director	Mr. Govinda Prasad Dasu
Independent Director	Mr. Umamaheshwarrao Naidu Madireddi
Independent Director	Mr. Venkateswara Rao Thallapaka
Non-Executive Director	Mr. Sridhar Sankararaman
Independent Director	Mrs. Leela Digumarti
6. Relatives of KMP	
	Mrs. Durga Devi Nannapaneni
	Dr. N. Ramakrishna Rao
	Mrs. V S Swathi Kantamani

(b) Related party transactions during the year
(All amounts in ₹ millions)

	For the year ended	
	31 March 2020	31 March 2019
Time Cap Overseas Limited, Mauritius		
Investment in equity shares	9	-
Share application money	-	2
Loan given	18	165
Interest income on loan	10	10
NATCO Pharma (Canada) Inc., Canada		
Sale of products	156	150
NATCO Pharma Asia Pte Ltd., Singapore		
Investment in equity shares	13	24
Loan given	-	108
Interest income on loan	6	1
Sale of products	14	7
Natcofarma Do Brasil Ltda., Brazil		
Sale of products	281	48
NATCO Pharma Australia Pty Ltd., Australia		
Investment in equity shares	4	7
NATCO Pharma Inc., United States of America		
Loan given	-	114
Interest income on loan	6	2
NATCO Lifesciences Philippines Inc., Philippines		
Investment in equity shares	24	12
Loan given	-	7
Interest income on loan	0	0
Time Cap Pharma Labs Limited		
Sales promotion expenses	-	6
Purchase of Land	-	49
Rental expense	5	5
NATCO Trust		
Donations	0	24
Contribution to corporate social responsibility activities	157	116

For NATCO Pharma Limited


S.V.V.N. APPA RAO
Chief Financial Officer

(b) Related party transactions during the year (continued)
(All amounts in ₹ millions)For the year ended
31 March 2020 31 March 2019

Mr. V C Nannapaneni		
Short-term employee benefits*	18	17
Leave encashment paid	1	1
Rental expense	2	2
Mr. Rajeev Nannapaneni		
Short-term employee benefits*	17	16
Leave encashment paid	1	1
Rental expense	3	1
Mr. Potluri Prasad Sivaramakrishna		
Short-term employee benefits*	18	14
Leave encashment paid	0	0
Mr. Lingarao Donthineni		
Short-term employee benefits*	18	14
Leave encashment paid	0	0
Mr. S.V.V.N. Appa Rao		
Short-term employee benefits*	9	6
Mr. Adinarayana M		
Short-term employee benefits*	5	4
Sitting fees:		
Mr. Govinda Prasad Dasu	0	0
Mrs. Leela Digumarti	0	0
Mr. Umamaheshwarrao Naidu Madireddi	0	0
Mr. Sreerama Murthy Gubbala	0	0
Mr. Venkateswara Rao Thallapaka	0	0

(c) Related party closing balances as on balance sheet date receivable/(payable):
(All amounts in ₹ millions)

	As at	
	31 March 2020	31 March 2019
Loan receivable		
NATCO Pharma Inc., United States of America	124	114
Time Cap Overseas Limited, Mauritius	289	247
NATCO Pharma Asia PTE Ltd., Singapore	111	108
NATCO Lifesciences Philippines Inc., Philippines	-	7
Interest receivable on loans		
NATCO Pharma Inc., United States of America	8	2
Time Cap Overseas Limited, Mauritius	11	9
NATCO Pharma Asia PTE Ltd., Singapore	4	1
Trade receivables		
NATCO Pharma (Canada) Inc., Canada	120	132
Natcofarma Do Brasil Ltda., Brazil	266	47
NATCO Pharma Asia PTE Ltd., Singapore	8	7
Trade payable		
Time Cap Pharma Labs Limited	-	(0)
Remuneration payable		
Mr. V.C. Nannapaneni	-	(2)
Mr. Rajeev Nannapaneni	(1)	(1)
Mr. Lingarao Donthineni	(3)	(1)
Mr. Potluri Prasad Sivaramakrishna	(3)	(1)
Mr. S.V.V.N. Appa Rao	0	0
Mr. Adinarayana M	0	0

*This aforesaid amount does not include amounts in respect of gratuity and compensated absences as the same are determined on actuarial basis for the Company as a whole.

For NATCO Pharma Limited


S.V.V.N. APPA RAO
Chief Financial Officer